During the past five years ganglion-blocking agents have been used extensively in the treatment of arterial hypertension. The discovery of the activity of hexamethonium by Paton and Zaimis (1949) placed at our disposal an active therapeutic agent capable of producing a substantial reduction in the blood pressure. Subsequent research has been directed to the synthesis of new drugs offering advantages over hexamethonium.
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During the past five years ganglion-blocking agents have been used extensively in the treatment of arterial hypertension. The discovery of the activity of hexamethonium by Paton and Zaimis (1949) placed at our disposal an active therapeutic agent capable of producing a substantial reduction in the blood pressure. Subsequent research has been directed to the synthesis of new drugs offering advantages over hexamethonium.
In the treatment of hypertension, it is desirable to obtain a sustained fall in the blood pressure by the oral administration of a drug producing a minimum of sideeffects. Hexamethonium is inconstant in action by mouth, its duration of action is short, and it produces side-effects characteristic of generalized ganglionic blockade. Maxwell and Campbell (1953) examined a number of methonium homologues and indicated the suitability of one of them, pentolinium, for therapeutic application. At present pentolinium is the most active hypotensive drug available and it has been widely employed. Trapold et al. (1955) have described the pharmacological actions of a new synthetic compound. " ecolid " (SU-3088), and Grimson et al. (1955) have demonstrated its activity in lowering the blood pressure in man. Trapold et al. (1955) have described a series of halogenated isoindolines with potent ganglion-blocking activity of long duration. Ecolid was the most active compound investigated. It is 4,5,6,7-tetrachloro-2-(2-dimethyl-aminoethyl)-isoindoline dimethochloride, the structural formula being as follows:
Cl CH3 ci /\I N-1 (CH2)2N+(CHS)3 (Cl)2 Cl The chloride salt contains 83.45% active cation. In animal experiments it was found that this new compound is several times as active in parenteral dosage as hexamethonium, and twice as active as pentolinium.. In oral dosage its activity is the same as pentolinium, but the duration of action is appreciably longer. Vagal activity is affected less than sympathetic. The relative shortness of the methylene chain is of interest. This suggests that the overall molecular length is of greater importance in obtaining a specific synaptic fit than the spacing between the quaternary nitrogen atoms.
Clinical Investigation Twelve patients were selected who had severe hypertension and whose blood pressures remained high, despite admission to hospital and treatment by bed rest, sedation, and dietary and salt restriction. Five of these patients (Cases 1-5) had been treated previously with various ganglion-blocking agents for several years, and their readmission to hospital was considered necessary owing to the recurrence of hypertension during out-patient treatment. All the patients were investigated fully as described by Graham and Maxwell (1954) . This series of patients formed a good test for a new ganglion-blocking agent, as the hypertension was severe in every case.
Ecolid was administered by mouth before breakfast, to facilitate absorption. During 85 observations it was found that the effective dose varied from 25 to 200 mg. In common with other ganglion-blocking agents, the response to the first dose was greater than that obtained subsequently, and higher dosage was required in those cases previously treated with sympathicolytics. In some cases a response was not obtained until the second or third day of treatment, suggesting a cumulative effect. A marked fall in blood pressure sometimes followed the initial dose of 25 mg. In every case adequate dosage produced a fall in blood pressure to the basal level, with increased peripheral blood flow as shown by a rise in temperature of the extremities, and postural hypotension. Evidence of vagal inhibition was present in the form of mydriasis, paralysis of accommodation, and dryness of the skin and mouth. Five barium examinations showed a variable depression of gastro-intestinal motility, this being marked after doses of over 150 mg. Postural syncope resembled that produced by pentolinium, loss of consciousness being slow and accompanied by nausea. The dose required to produce a marked fall in blood pressure was rather less than that of pentolinium, and the duration of action was approximately double. These results are compared with those from hexamethonium in the Chart. During the last four months ecolid has been used in the treatment of this series of 12 patients. It was found possible to lower the blood pressure to a satisfactory level in every case. The severity of the side-effects depended to some extent upon the dosage used. Mydriasis was a constant finding, and blurring of vision commonly occuired during initial treatment, but was less severe with maintenance dosage. Precautions were necessary to overcome development of constipation, and in three cases treatment had to be stopped owing to nausea and vomiting and obdurate constipation. A preference for pentolinium was expressed by two patients (Cases 2 and 5) who have had extensive experience of ganglion-blocking agents. Bain et al. (1955) have shown that combination of reserpine with pentolinium enabled reduction in dosage of the latter and thereby a decrease in side-actions. Combined dosage of reserpine and ecolid was used in the maintenance treatment of Cases 7-12, reserpine, 2 mg. by mouth, being ECOLID BRITISH MEDICAL JOURNAL given in the evening. Reduction in the maintenance dosage of ecolid was possible and side-effects were fewer. During the period of observation, tolerance to ecolid has not developed, and in some cases reduction of dosage has been possible. The response was good in eight cases and fair in one, the drug being stopped in the remaining three owing to severity of side-actions. These results are summarized in the Discussion The introduction of ganglion-blocking agents in the treatment of hypertension is due to the work of Dale (1914) , who described the properties of tetraethylammonium (T.E.A.). Recognizing the improvement which could be obtained by surgical procedures in patients with severe hypertension, Lyons et al. (1947) (1949) showed that the bis-quaternary amine hexamethonium was a practical method of lowering the blood pressure. However, the generalized activity of this drug proved to be a handicap, as its actions, beyond inhibition of sympathetic ganglia, constituted side-effects. The serious complication of ileus, due to vagal block, has been described. . Paton (1951) suggested that it might be possible to produce ganglion-blocking agents more or less adapted to different ganglionic systems. It was with this purpose that Maxwell and Campbell (1953) investigated a large number of new drugs inhibiting synaptic transmission. Pentolinium was found active in lowering the blood pressure in smaller doses than hexamethonium, and it had only a weak action on gastric secretomotor activity. It is effective by mouth in a high proportion of cases, and it has been combined successfully in oral dosage with reserpine.
The research by Trapold et al. (1955) has been concerned mainly with the production of a ganglion-blocking agent consistently active by mouth. Ecolid has met this requirement and has also a longer duration of action than pentolinium. This 
Medical Memoranda Delayed Onset of Signs in Extradural Haemorrhage
Variations in the clinical picture resulting from extradural haemorrhage are common, but it is unusual for the development of signs of cerebral compression to be delayed for more than 24 hours after the receipt of injury. The compression, once initiated, is usually rapidly progressive, leading to death within 48 hours if unrelieved. In the following case, consciousness was never lost, the onset of clinical signs was insidious, and operation was not performed until six days after injury. CASE REPORT On September 1, 1954, a boy aged 12 was riding downhill on his bicycle when the brakes failed. To stop the bicycle he put a foot between the spokes of the front wheel and was thrown over the handlebars, striking the right side of' his head and his right leg on the ground. He did not lose consciousness, but vomited three times.
On admission to hospital he was found to be alert and bright, with good recollection of events before and after the accident. There were bruises in the right temporal region and over the right shin. The left eye had been removed in infancy following an injury, but the pupillary reactions on the right side were brisk and the optic fundus was normal. There was considerable haemorrhage from the right ear, and radiography showed a fine vertical fracture of the squamous part of the temporal bone on the right side.
The pulse rate was 64.
Next day, apart from a little headache, the boy was well and the bleeding from the ear had stopped. Two days later
